Hims & Hers Health (NYSE:HIMS) Shares Gap Down – What’s Next?

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price gapped down prior to trading on Tuesday . The stock had previously closed at $27.88, but opened at $26.46. Hims & Hers Health shares last traded at $27.18, with a volume of 3,419,804 shares trading hands.

Analyst Upgrades and Downgrades

HIMS has been the subject of several recent analyst reports. Canaccord Genuity Group raised their price objective on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft raised their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Bank of America boosted their price objective on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Piper Sandler reaffirmed a “neutral” rating and issued a $21.00 price target (up from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Finally, Imperial Capital downgraded shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research report on Friday, August 9th. Eight equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $21.21.

Hims & Hers Health Stock Up 3.4 %

The company’s fifty day moving average is $19.51 and its two-hundred day moving average is $18.77. The firm has a market capitalization of $5.93 billion, a price-to-earnings ratio of 62.73 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The company had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the prior year, the business posted ($0.04) EPS. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Soleil Boughton sold 2,339 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the sale, the insider now owns 169,935 shares of the company’s stock, valued at approximately $3,935,694.60. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $23.16, for a total value of $54,171.24. Following the completion of the transaction, the insider now owns 169,935 shares of the company’s stock, valued at $3,935,694.60. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $14.56, for a total value of $2,750,209.28. Following the sale, the chief executive officer now directly owns 33,502 shares in the company, valued at $487,789.12. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 854,547 shares of company stock worth $15,987,230. 17.71% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the business. Nisa Investment Advisors LLC lifted its stake in Hims & Hers Health by 679.2% in the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC lifted its position in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares in the last quarter. CWM LLC boosted its stake in Hims & Hers Health by 21.4% in the 3rd quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the period. Van ECK Associates Corp bought a new position in Hims & Hers Health during the 2nd quarter worth about $111,000. Finally, Amalgamated Bank raised its stake in shares of Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the period. 63.52% of the stock is currently owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.